

b(4)

**Table 24: Seizure-related AE dropouts in LCM in EP S1, treatment phase**

| MedDRA<br>PT term  | Placebo<br>(N=364)<br>n (%) | LCM (mg/day)            |                         |                         |                               |
|--------------------|-----------------------------|-------------------------|-------------------------|-------------------------|-------------------------------|
|                    |                             | 200<br>(N=270)<br>n (%) | 400<br>(N=471)<br>n (%) | 600<br>(N=203)<br>n (%) | LCM Total<br>(N=944)<br>n (%) |
| Any                | 4 (1.1)                     | 2 (0.7)                 | 10 (2.1)                | 0                       | 12 (1.3)                      |
| Convulsion         | 4 (1.1)                     | 2 (0.7)                 | 8                       | 0                       | 10                            |
| Status epilepticus | 0                           | 0                       | 2                       | 0                       | 2                             |

Source, Summary of Clinical Safety, Table EP.6.29.1.

The overall rate of cases of seizure activity leading to discontinuation in this database is similar between placebo and LCM treated patients. It is unclear why LCM 400 appears to have a higher rate than the LCM 200 and LCM 600 groups. The listing of cases in which seizure activity led to a study discontinuation is presented as follows:

**Table 25. Lacosamide. Dropouts due to seizure-related adverse event EP Pool S1**

| ID        | TrtGroup | AE term                                 | LLT                    | PT                 | Rel st<br>day | Serious | Outcome         | AE dose |
|-----------|----------|---|------------------------|--------------------|---------------|---------|-----------------|---------|
| 667015009 | Placebo  | Increase of Sz frequency                | Convulsions aggravated | Convulsion         | 100           | Yes     | R with sequelae | 0       |
| 754012010 | Placebo  | Increased of seizures                   | Convulsions aggravated | Convulsion         | 2             | No      | R               | 0       |
| 754018303 | Placebo  | Flurry of seizures                      | Convulsions aggravated | Convulsion         | 41            | No      | R               | 0       |
| 755118104 | Placebo  | Seizures increase                       | Convulsions aggravated | Convulsion         | 82            | No      | R               | 0       |
| 667011910 | LCM 200  | Increased number of Sz                  | Convulsions aggravated | Convulsion         | 1             | Yes     | R               | 0       |
| 755118617 | LCM 200  | Seizures increase                       | Convulsions aggravated | Convulsion         | 26            | No      | R               | 200     |
| 667010404 | LCM 400  | Seizures                                | Seizures               | Convulsion         | 99            | Yes     | R               | 400     |
| 667014801 | LCM 400  | Worsening Sz change in "aura"           | Convulsions aggravated | Convulsion         | 17            | No      | R               | 100     |
| 754010107 | LCM 400  | Status epilepticus                      | Status epilepticus     | Status epilepticus | 31            | Yes     | R               | 400     |
| 754013604 | LCM 400  | Increased Sz frequency, hospitalization | Convulsions aggravated | Convulsion         | 1             | Yes     | R               | 100     |
| 754017202 | LCM 400  | Worsening of seizures                   | Seizure                | Convulsion         | 21            | No      | R               | 300     |
| 754019001 | LCM 400  | Increased Sz frequency                  | Convulsions aggravated | Convulsion         | 20            | No      | R               | 300     |
| 755108202 | LCM 400  | Hospitalization status epileptic        | Status epilepticus     | Status epilepticus | 123           | Yes     | R               | 0       |
| 755118106 | LCM 400  | Seizures increase                       | Convulsions aggravated | Convulsion         | 31            | No      | R               | 400     |
| 755118211 | LCM 400  | Seizures increase                       | Convulsions aggravated | Convulsion         | 3             | No      | R               | 100     |

b(4)

Clinical Safety Review  
 Lourdes Villalba, M.D.  
 NDA 22-253, -254, — Lacosamide for the treatment of partial-onset seizures

| ID        | TrtGroup | AE term              | LLT                    | PT         | Rel st day | Serious | Outcome | AE dose |
|-----------|----------|----------------------|------------------------|------------|------------|---------|---------|---------|
| 755118613 | LCM 400  | Increase of seizures | Convulsions aggravated | Convulsion | 13         | No      | No RE   | 200     |

LLT= MedDRA lower level term. Source: AE datasets in EP S1.

The mean and median doses at the time of the onset of the AE of seizure among patients randomized to LCM were 208 mg/day and 200 mg/day, respectively. No seizure-related events occurred in patients while receiving 500 and 600 mg/day. This is reassuring, as higher doses of LCM do not seem to be associated with an increased risk of seizures leading to dropout.

- Dropouts due to AEs in other SOCs

Table 26 summarizes PT terms for AEs in other SOCs with >1% incidence of discontinuations.

**Table 26. Lacosamide NDA. Patients who discontinued from EP Pool S1, by preferred term in selected SOCs1, during the treatment phase by randomized dose.**

| MedDRA System Organ Class                | Placebo (N=364)<br>n (%) | LCM (mg/day)         |                      |                      | LCM Total (N=944)<br>n (%) |
|--|--------------------------|----------------------|----------------------|----------------------|----------------------------|
|  |                          | 200 (N=270)<br>n (%) | 400 (N=471)<br>n (%) | 600 (N=203)<br>n (%) |                            |
| Gastrointestinal disorders               | 3 (0.8)                  | 3 (1.1)              | 15 (3.2)             | 12 (5.9)             | 30 (3.2)                   |
| Vomiting                                 | 3                        | 1                    | 11 (2.3)             | 6 (3.0)              | 18 (1.9)                   |
| Nausea                                   | 1                        | 1                    | 8 (1.7)              | 8 (3.9)              | 17 (1.8)                   |
| Flatulence                               | 1                        | 0                    | 1                    | 1                    | 2                          |
| Diarrhea                                 | 0                        | 0                    | 1                    | 0                    | 1                          |
| Pancreatitis                             | 0                        | 0                    | 1                    | 0                    | 1                          |
| Abdominal pain/ abd pain upper           | 1                        | 1                    | 0                    | 0                    | 1                          |
| Dry mouth                                | 0                        | 1                    | 0                    | 0                    | 1                          |
| Eye disorders                            | 1 (0.3)                  | 5 (1.9)              | 13 (2.8)             | 10 (4.9)             | 28 (3.0)                   |
| Diplopia                                 | 1                        | 4 (1.5)              | 10 (2.1)             | 4 (2.0)              | 18 (1.9)                   |
| Vision blurred                           | 0                        | 1                    | 3                    | 6 (3.0)              | 10 (1.1)                   |
| Photopsia                                | 0                        | 0                    | 1                    | 0                    | 1                          |
| General disorders and admin site condit. | 1 (0.3)                  | 2 (0.7)              | 6 (1.3)              | 8 (3.9)              | 16 (1.7)                   |
| Fatigue                                  | 1                        | 0                    | 3 (0.7)              | 3 (1.5)              | 6                          |
| Asthenia                                 | 0                        | 0                    | 0                    | 4 (2.0)              | 4                          |
| Chest pain                               | 0                        | 2                    | 0                    | 1                    | 3                          |
| Malaise                                  | 0                        | 0                    | 2                    | 0                    | 2                          |
| Feeling cold                             | 0                        | 0                    | 0                    | 1                    | 1                          |
| Feeling abnormal                         | 0                        | 0                    | 1                    | 0                    | 1                          |
| Feeling drunk                            | 0                        | 0                    | 1                    | 0                    | 1                          |

b(4)

| MedDRA System Organ Class   | Placebo (N=364) n (%) | LCM (mg/day)      |                   |                   |                         |
|---|-----------------------|-------------------|-------------------|-------------------|-------------------------|
|   |                       | 200 (N=270) n (%) | 400 (N=471) n (%) | 600 (N=203) n (%) | LCM Total (N=944) n (%) |
| Psychiatric disorders   | 0                     | 1 (0.4)           | 10 (2.1)          | 4 (2.0)           | 15 (1.6)                |
| Depression/depr. Suicidal /suic. attempt                          | 0                     | 1                 | 3                 | 1                 | 5                       |
| Confusional state/Mental status changes                           | 0                     | 0                 | 4                 | 0                 | 4                       |
| Insomnia  | 0                     | 0                 | 0                 | 1                 | 1                       |
| Tearfulness   | 0                     | 0                 | 0                 | 1                 | 1                       |
| Bradyphrenia  | 0                     | 0                 | 0                 | 1                 | 1                       |
| Euphoric mood   | 0                     | 0                 | 1                 | 0                 | 1                       |
| Psychotic disorder  | 0                     | 0                 | 1                 | 0                 | 1                       |
| Ear and labyrinth disorders (All Vertigo or Vestibular disorders) | 0                     | 3 (1.1)           | 5 (1.1)           | 5 (2.5)           | 13 (1.4)                |
| Skin and subcutaneous tissue disorders                            | 2 (0.5)               | 0                 | 5 (1.1)           | 1 (0.5)           | 6 (0.6)                 |
| Rash  | 2 (0.2)               | 0                 | 2 (0.4)           | 0                 | 2 (0.2)                 |
| Pruritus  | 0                     | 0                 | 0                 | 1 (0.5)           | 1 (0.1)                 |
| Hyperhidrosis   | 0                     | 0                 | 1 (0.2)           | 0                 | 1 (0.1)                 |
| Night sweats  | 0                     | 0                 | 1 (0.2)           | 0                 | 1 (0.1)                 |
| Urticaria   | 0                     | 0                 | 1 (0.2)           | 0                 | 1 (0.1)                 |

1 SOCS with ≥ 1% discontinuations (other than the Nervous System) in at least one treatment group. Note: Treatment Phase includes both Titration and Maintenance Phase data. Note: n = Number of subjects who reported at least one event during the phase. % = Percent with respect to the number of subjects in Pool S1. Source, Summary of Clinical Safety, Table EP.6.29.1.

Most of the GI and eye disorders leading to dropout are likely related to LCM. The cases of pancreatitis and peritonitis have been mentioned under SAEs and did not appear to be drug related. Asthenia, fatigue, malaise have been observed in phase 1 studies and are likely related to LCM. Psychiatric AEs and Skin rash and hypersensitivity will be discussed later under section 7.1.4 (AE of interest).

A table summarizing AE that led to discontinuations in SOCs that had an incidence <1.0% in EP S1 is in Appendix 7.

There were few dropouts due to cardiac disorders in the epilepsy population. They all occurred in the LCM treatment group. These cases are discussed in Section 7.1.4.1 of this review (AE of interest, Cardiac AEs).

Of note, in the placebo-controlled DPN studies five patients discontinued the study because of syncope/loss of consciousness. All five cases occurred in the LCM treatment group at doses of 400 and 600 mg/day (5/1023= 0.5% among LCM-treated patients and 0% among placebo). For details the reader is referred to Dr. Pokrovnichka's clinical review.

### 7.1.3.3 Adverse events leading to dose reduction in EP S1

On Feb 19, 2008, at the FDA's request, the sponsor submitted a summary table of TEAE that led to either dose reduction or discontinuation in all three placebo controlled studies (See Table below).

This analysis (by randomization dose) shows a dose response in terms of AE leading to dose reduction particularly for those SOC's with the larger numbers of events. Overall approximately half of AE that required dose reduction underwent discontinuation. Depending on the SOC, a different fraction of cases that underwent dose reduction ended up requiring discontinuation. The SOC that most led to dose reduction/discontinuation was the Nervous System Disorders SOC (18.6%) followed by Eye disorders (7.2%) and GI disorders (5.1%). Approximately half of the patients who required dose reduction ended up being withdrawn from the studies.

*Comment: A summary table for AE that led to dose reduction in the epilepsy studies by randomization dose was submitted with the original application for SP754 and SP755 only. Dose reduction in study SP667 (US and non-US) had not been not prospectively identified/analyzed. Information from all three studies was submitted later in February 2008.*

A summary of TAE that led to dose reduction or dropout in EP Pool S1, treatment phase, by SOC and randomization dose is presented in the next table.

**APPEARS THIS WAY  
ON ORIGINAL**

b(4)

**Table 27. TAE that led to dose reduction or discontinuation in EP Pool S1, treatment phase, by SOC and randomization dose**

| MedDRA System Organ Class   | Placebo (N=364) n (%) | LCM (mg/day)      |                   |                   |                         |
|---|-----------------------|-------------------|-------------------|-------------------|-------------------------|
|   |                       | 200 (N=270) n (%) | 400 (N=471) n (%) | 600 (N=203) n (%) | LCM Total (N=944) n (%) |
| Any system organ class  | 26 (7.1)              | 42 (15.6)         | 141 (29.9)        | 94 (46.3)         | 277 (29.3)              |
| Blood and lymphatic system disorders                                | 0                     | 2 (0.7)           | 1 (0.2)           | 0                 | 3 (0.3)                 |
| Cardiac disorders   | 0                     | 1 (0.4)           | 3 (0.6)           | 0                 | 4 (0.4)                 |
| Ear and labyrinth disorders   | 0                     | 5 (1.9)           | 12 (2.5)          | 6 (3.0)           | 23 (2.4)                |
| Endocrine disorders   | 0                     | 1 (0.4)           | 0                 | 0                 | 1 (0.1)                 |
| Eye disorders   | 1 (0.3)               | 9 (3.3)           | 32 (6.8)          | 27 (13.3)         | 68 (7.2)                |
| Gastrointestinal disorders  | 4 (1.1)               | 7 (2.6)           | 23 (4.9)          | 18 (8.9)          | 48 (5.1)                |
| General disorders and admin site condit.                            | 2 (0.5)               | 4 (1.5)           | 17 (3.6)          | 12 (5.9)          | 33 (3.5)                |
| Hepatobiliary disorders   | 0                     | 0                 | 1 (0.2)           | 1 (0.5)           | 2 (0.2)                 |
| Infections and infestations   | 0                     | 0                 | 5 (1.1)           | 1 (0.5)           | 6 (0.6)                 |
| Injury, poisoning and procedural complic.                           | 0                     | 1 (0.4)           | 3 (0.6)           | 2 (1.0)           | 6(0.6)                  |
| Investigations  | 1 (0.3)               | 5 (1.9)           | 7 (1.5)           | 3 (1.5)           | 15 (1.6)                |
| Metabolism and nutrition disorders                                  | 0                     | 2 (0.7)           | 1 (0.2)           | 1 (0.5)           | 4 (0.4)                 |
| Musculoskeletal and connective tissue dis.                          | 1 (0.3)               | 1 (0.4)           | 3 (0.6)           | 3 (1.5)           | 7 (0.7)                 |
| Neoplasms benign, malignant and Unspecified (incl cysts and polyps) | 1 (0.3)               | 1 (0.4)           | 0                 | 0                 | 1 (0.1)                 |
| Nervous system disorder   | 14 (8.0)              | 21(7.8)           | 84 (17.8)         | 71 (35.0)         | 176 (18.6)              |
| Psychiatric disorders   | 0                     | 3 (1.1)           | 14 (3.0)          | 5 (2.5)           | 22 (2.3)                |
| Respiratory, thoracic and mediastinal dis.                          | 0                     | 0                 | 1 (0.2)           | 0                 | 1 (0.1)                 |
| Skin & SC tissue disorders  | 2 (0.5)               | 0                 | 7 (1.5)           | 1 (0.5)           | 8 (0.8)                 |
| Vascular disorders  | 1 (0.3)               | 1 (0.4)           | 0                 | 0                 | 1 (0.1)                 |

Source: February 19, 2008 response to FDA request for information.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.